PMBS - der Ausbruch kommt !

Seite 1 von 11
neuester Beitrag: 25.04.21 01:01
eröffnet am: 19.01.14 14:24 von: Tuedi2005 Anzahl Beiträge: 266
neuester Beitrag: 25.04.21 01:01 von: Mariaxppea Leser gesamt: 23140
davon Heute: 8
bewertet mit 3 Sternen

Seite: 1 | 2 | 3 | 4 |
8 | 9 | 10 | 11 | 11   

19.01.14 14:24
3

1577 Postings, 3977 Tage Tuedi2005PMBS - der Ausbruch kommt !

PuraMed Bioscience was founded in 2006 and is based in Schofield, Wisconsin. The company began trading under the symbol PMBS in May 2008.

PuraMed engages in the research, development and marketing of non-prescription medicinal and healthcare products. The company emphasizes science as a key component for its success. By partnering with world-class researchers and physicians to conduct and publish world-class research on its products, PuraMed believes it will gain acceptance and credibility from consumers and medical professionals at a much faster and greater rate.

For its initial product line, the company uses a unique sublingual (under the tongue) delivery system, taking advantage of the capillary structure under the tongue which is very close to the surface. Sublingual delivery enables fast absorption and action. It also bypasses the liver and digestive system, avoiding the destruction of the active ingredients by these organs. This allows for lower dosage requirements and increased safety.

PuraMed is currently launching its first product, LipiGesic® M for the treatment of migraine headaches, into the U.S. national retail market. This is a very large market, with approximately 50 million sufferers in the U.S. alone. Migraine headaches are considered to be the most expensive brain disorder in the U.S., costing the economy more than $31 billion in 2010.

A multi-site, double-blind placebo-controlled study, conducted by three nationally recognized headache specialists, was published in a top-tier medical journal in July 2011. This study concluded that LipiGesic M is a highly effective and safe first-line abortive treatment for migraine sufferers. When compared to a meta-analysis of the number one selling prescription treatment, the results of the LipiGesic® M study show it offers a number of advantages. In addition to superior pain relief, LipiGesic® M provides relief from the associated symptoms. It also offers a vastly improved safety profile, no known drug interactions, does not require a physician visit or prescription, and it cuts the treatment cost by at least 75%. These are very powerful advantages, especially for a non-prescription treatment.

In addition to LipiGesic® M, the company also intends to launch two other sublingual gel products in its LipiGesic product line. LipiGesic® H is designed to provide rapid relief from tension-type headaches. More than 100 million people suffer from chronic and episodic tension-type headaches in the U.S. LipiGesic PM is designed to provide relief from insomnia and other sleep disorders. There are more 70 million people who suffer from sleep disorders in the U.S. alone.

The LipiGesic product line effectively addresses three large underserved markets. In addition, the company has approximately 20 other unique products in its pipeline, addressing a broad spectrum of self-limiting disease states including acne, rosacea, age spots and canker sores.

The company believes that by improving the efficiency of delivery, it can provide products that offer superior relief versus current treatment while also dramatically increasing safety and cutting treatment costs significantly.

Market Drivers

   50 million migraine sufferers
   70 million insomnia sufferers
   Total economic cost of migraine headaches exceeded $31 Billion in the United States in 2010. Migraine headaches represent the most costly brain disorder in the United States.
   By using sublingual (under the tongue) delivery, the medication is able to work much faster than taking pills.
   Sublingual delivery also avoids the "first pass" effect, common with the use of pills, whereby the strength of a drug is greatly reduced before it reaches the systemic circulation. Avoiding this "first pass effect" allows for lower dosages.
   Company founders have experience that includes placing products in 50,000 stores nationwide through its brokers and representatives. This enables the Company to achieve broad distribution quickly and at low cost.
   There are NO serious adverse events associated with LipiGesic® products for migraine, insomnia or tension headaches.

Unique PuraMed Delivery System

Sublingual delivery (meaning under the tongue) is a superior delivery system to pills because the sublingual delivery works much faster and lower dosage is required. The capillaries under the tongue are extremely close to the surface creating very fast absorption and action. Sublingual delivery not only works faster than most other delivery systems but it also avoids the "first pass" effect, common with the use of pills, whereby the strength of a drug is greatly reduced before it reaches the systemic circulation. Avoiding this "first pass effect" allows for lower dosages.
Distribution

Non-prescription products reach U.S. consumers through approximately 80,000 chain and independent drug, food and mass merchandise retailers (including club stores), 116,000 convenience stores, 4,500 specialty nutrition and health stores, as well as via direct marketing through television, radio, catalogues and the Internet. PuraMed plans to market and distribute its products through mainstream chain drug, independent drug, mass merchandiser, food and warehouse stores. Company founders have experience that includes placing products in 50,000 stores nationwide through its brokers and representatives. This background will enable the Company to achieve broad distribution quickly and at better rates.
RECENT HIGHLIGHTS

   Distributing product in Walgreens stores across the nation, with additional key retail chains to follow.

News and Developments

   PuraMed BioScience announced today that the independent clinical study of their LipiGesic® M migraine product has been accepted for publication by a top ranked medical journal. The clinical study design was a double blind, placebo controlled, multi-site study measuring the effectiveness of LipiGesic® M for the treatment of acute migraines.
   PuraMed BioScience announced today that it has entered into an agreement with Double Pump, Inc. designed to enhance marketing efforts and product awareness surrounding the national retail launch of the Company"s products.

Market Opportunity

LipiGesic® M ? Migraine

   Over 50 million suffer
   1 billion + occurrences/yr.
   Majority rely on non prescription medications
   Current migraine relief products are marginally effective and have significant side effects
   No "alternative" competition
   Bests "standard" products
   Recurring, non-seasonal
   Unique delivery platform

LipiGesic® H ? Tension

   Over 102 million suffer from chronic and episodic tension-type headache
   1 billion occurrences/year
   Current tension relief products are marginally effective and have significant side effects
   No "alternative" competition
   Bests "standard" products
   Recurring, non-seasonal
   Unique delivery platform

LipiGesic® PM -Insomnia

   70 million suffer
   5 billion occurrences/yr.
   Current insomnia products are marginally effective and have significant side effects
   No "alternative" competition
   Bests "standard" products
   Recurring, non-seasonal
   Unique delivery platform

 
Seite: 1 | 2 | 3 | 4 |
8 | 9 | 10 | 11 | 11   
240 Postings ausgeblendet.

16.04.14 18:05

2500 Postings, 4607 Tage ChristkindlRT 39

die 30 hat gehalten.....und jetzt große Käufe und das ohne News....
das soll einer verstehen...?
-----------
Börse ist keine Einbahnstraße!!!

16.04.14 18:44

357 Postings, 2641 Tage stksat|228724723Heute toller Move bei PMBS...

16.04.14 19:33

2433 Postings, 3064 Tage Bob der Bobglaub ans glück...

16.04.14 19:34

2433 Postings, 3064 Tage Bob der Bobwird aber leider nix...

Dilution ohne ende...  

16.04.14 19:58

357 Postings, 2641 Tage stksat|228724723Bis dato ja...

...da helfen eben nur reale Produkte und reale Einnahmen...  

17.04.14 18:24

3624 Postings, 3183 Tage Cancun25Neeeee, und dann...?

17.04.14 20:31

357 Postings, 2641 Tage stksat|228724723Dann...

...gibts erst mal 4,000,000,000 Shares...  

17.04.14 20:33

3624 Postings, 3183 Tage Cancun25mehr nicht...

ist ja ein Witz...  

25.04.14 20:01

2433 Postings, 3064 Tage Bob der Bobwer hat der hat...

28.04.14 06:52

357 Postings, 2641 Tage stksat|228724723joint venture

A/s INCREASE- will be used for joint ventures, which is a key component of surviving the mj industry. 
http://investorshub.advfn.com/boards/...msg.aspx?message_id=101181894  

28.04.14 18:04

2500 Postings, 4607 Tage Christkindldie 0,002

haben wir inzwischen gesehen, jetzt
kann man auch davon ausgehen, dass wir auf 0,0015 zurückfallen, wenn nicht bald eine positive News rauskommt. Ich meine eine News mit Fakten und keine Glaubensgeschichten wie erst kürzlich.....Das Gesabber aus dem Ihub bringt auch keinem was........
Mal sehen wie´s weitergeht....
-----------
Börse ist keine Einbahnstraße!!!

01.05.14 14:17

2500 Postings, 4607 Tage ChristkindlCurrent Report Filing (8-k)

http://ih.advfn.com/p.php?pid=nmona&article=62033509

und dazu der evtl. weitere Chartverlauf, wobei ich immer noch hoffe mich zu irren......
-----------
Börse ist keine Einbahnstraße!!!
Angehängte Grafik:
chart_year_puramedbioscience.jpg (verkleinert auf 70%) vergrößern
chart_year_puramedbioscience.jpg

01.05.14 20:19

357 Postings, 2641 Tage stksat|228724723Wie lange dauert der Verwässerungszauber?

Wird sich weisen was PMBS mit der Kohle wirklich auf den Boden bringt...  

15.05.14 21:11

357 Postings, 2641 Tage stksat|228724723Bodenbildung?

Scheint mal den Boden um die 0015 - 0017 gefunden zu haben...jetzt sollten dann mal Fakten gemeldet werden, damit der Restart losgehen kann.  

15.05.14 21:28

357 Postings, 2641 Tage stksat|228724723Notification

PMBS ist leider nicht mehr OTCQB gelistet. Erste Auswirkungen?

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

ttp://ih.advfn.com/p.php?pid=nmona&article=62222299  

17.05.14 03:46

357 Postings, 2641 Tage stksat|228724723Daytrader

haben sicher eine Freude bei dieser Tagesrange, trotz oder wegen Dilution...  
Angehängte Grafik:
screenshot_2014-05-17-03-29-08-1-1.jpg (verkleinert auf 48%) vergrößern
screenshot_2014-05-17-03-29-08-1-1.jpg

23.05.14 19:51

357 Postings, 2641 Tage stksat|228724723Mittlerweile haben wir die Fakten...

Net revenue for the three months ended March 31, 2014 and 2013 was $0.   

http://ih.advfn.com/p.php?pid=nmona&article=62277640

 

24.05.14 22:56

1420 Postings, 2704 Tage Insider86so ist das bei ner Briefkastenfirma :-D

11.08.14 16:12

15800 Postings, 3282 Tage nordküstenbauPuramed Bio

auch ein Pharmaziewert der jede Menge Potenial nach oben hat, wenn sie mal anläuft  

12.08.14 17:48

15800 Postings, 3282 Tage nordküstenbauPuraMed BioScience

alles ist möglich, ab 0,0003 USD  

09.10.14 07:14

17 Postings, 2751 Tage Thorsten0676was ist da los?

in meinem Depot wird der Kurs mit 0,49 USD ausgewiesen.
Verkaufen kann ich aber nicht.
Weiß jemand näheres?
Resplit??????  

25.04.21 01:01

8 Postings, 59 Tage MariaxppeaLöschung


Moderation
Zeitpunkt: 26.04.21 11:03
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer, Beitrag wird nicht mehr angezeigt.
Kommentar: Spam

 

 

Seite: 1 | 2 | 3 | 4 |
8 | 9 | 10 | 11 | 11   
   Antwort einfügen - nach oben
Werbung
finanzen.net Brokerage
finanzen.net Zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln